Quantcast Link Between Gluten and Immune Reaction Revealed for HLA-DQ8 Celiac Disease | NFCA
Skip Navigation Links

Link Between Gluten and Immune Reaction Revealed for HLA-DQ8 Celiac Disease

Share |

 
12/28/2012

The below is a portion of a press release from ImmusanT, an early stage biotechnology company focused on developing a treatment and a set of diagnostic and monitoring tools to manage patients with celiac disease.

CAMBRIDGE, Mass., -- A link between gluten and the immune system has literally been visualized in new research published today in a leading scientific journal, Immunity. The discovery is the collaborative work of research groups in Australia, the Netherlands and ImmusanT Inc. based in Cambridge, Massachusetts, led by Professor Jamie Rossjohn and Dr. Hugh Reid at Monash University, Dr. Bob Anderson of ImmusanT and Professor Frits Koning at the University of Leiden.

The use of x-ray crystallography enabled the researchers to visually determine how T cells interact with gluten that causes celiac disease in patients who have the DQ8 susceptibility gene, thereby providing insight into how celiac disease pathology is triggered. About half the population is genetically susceptible to celiac disease because they carry the immune response genes HLA-DQ2 or HLA-DQ8. At least one in 20 people who carry HLA-DQ2 and about one in 150 who have HLA-DQ8 develop celiac disease, but people with other versions of the HLA-DQ genes are protected.

This has led researchers to question how the immune system senses gluten.

"This is the first time that the intricacies of the interaction between gluten and two proteins that initiate immune responses have been visualized at a sub-molecular level. It is an important breakthrough for celiac disease and autoimmune disease," stated Professor Jamie Rossjohn , National Health and Medical Research Fellow, Monash University.

This central event in celiac disease is of scientific and commercial interest. ImmusanT is currently developing a blood test and a therapeutic vaccine, Nexvax2®, for patients with celiac disease who carry HLA-DQ2. Nexvax2 uses three gluten peptides commonly recognized by gluten-reactive T cells. Nexvax2 is intended to restore immune tolerance to gluten and allow patients to return to a normal diet including gluten.

Future studies will investigate whether T cell activation by gluten in patients with HLA-DQ2 follows similar principles.

Dr. Bob Anderson , Chief Scientific Officer at ImmusanT commented, "Because we now know the gluten peptides responsible for celiac disease, this is a unique opportunity to interrogate the molecular events leading to a self-destructive immune response."

About ImmusanT Inc.
ImmusanT is a privately-held biotechnology company focused on restoring tolerance to gluten in celiac disease by harnessing new discoveries in immunology that aim to improve diagnosis and treatment and return patients to a normal diet, good health and improved quality of life. The company is developing Nexvax2®, a therapeutic vaccine for celiac disease, and a companion diagnostic and monitoring tool to improve celiac disease management. ImmusanT's targeted immunotherapy discovery platform can be applied to a variety of epitope-specific autoimmune diseases. More information can be found at www.ImmusanT.com.
 

Note: NFCA maintains the position that views and information presented on articles and websites we link to are those of the authors, and not necessarily those of NFCA.
 

<< Back to Research News


 

 
 
  • Have you or your family members been diagnosed?
    Complete our celiac disease symptoms checklist today to find out if you are at risk of having celiac disease / gluten intolerance. We can help improve the quality of your life!
  • Stay Informed!
    Join our monthly newsletter to receive news, updates, and tips for healthy gluten-free living and information about celiac disease. Sign-up for the monthly e-mail newsletter